What medications are indicated for a patient with heart failure with reduced ejection fraction (HFrEF) who is New York Heart Association (NYHA) class II‑b?

Medications for HFrEF NYHA Class II

All patients with HFrEF NYHA Class II require four foundational medication classes started simultaneously or in rapid sequence: an ACE inhibitor (or ARNI), a beta-blocker (bisoprolol, carvedilol, or metoprolol succinate), a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor (dapagliflozin or empagliflozin), plus diuretics as needed for congestion. 1, 2, 3

Core Medication Classes (Class I Recommendations)

1. Renin-Angiotensin System Inhibition

• Start with an ACE inhibitor (enalapril 2.5 mg twice daily, lisinopril 2.5-5 mg daily, or ramipril 1.25 mg daily) 1, 4
• Consider ARNI (sacubitril/valsartan) as replacement for ACE inhibitor once patient is stable on ACE inhibitor therapy, starting at 24/26-49/51 mg twice daily 1, 2, 3
• If ACE inhibitor intolerant (cough, angioedema), use ARB (candesartan 4-8 mg daily, losartan 25-50 mg daily, or valsartan 40 mg twice daily) 1

2. Beta-Blockers (Evidence-Based Only)

Use only one of these three proven to reduce mortality 5, 1, 6, 1, 2, 3:

• Bisoprolol: Start 1.25 mg once daily, target 10 mg once daily
• Carvedilol: Start 3.125 mg twice daily, target 25 mg twice daily (<85 kg) or 50 mg twice daily (≥85 kg)
• Metoprolol succinate: Start 12.5-25 mg daily, target 200 mg daily

3. Mineralocorticoid Receptor Antagonists

• Spironolactone 12.5-25 mg once daily (target 25-50 mg daily) OR
• Eplerenone 25 mg once daily (target 50 mg daily) 1, 2, 3
• Requires eGFR >30 mL/min/1.73 m² and potassium <5.0 mEq/L 1, 2

4. SGLT2 Inhibitors (Newest Addition to Foundational Therapy)

• Dapagliflozin 10 mg once daily OR
• Empagliflozin 10 mg once daily 4, 2, 3
• Start early—benefits emerge within weeks 7
• No need to wait for diabetes diagnosis; indicated for all HFrEF 2, 3

5. Diuretics (Symptomatic Relief)

• Loop diuretics (furosemide 20-40 mg once or twice daily, bumetanide 0.5-1 mg, or torsemide 10-20 mg) for any signs/symptoms of congestion 1, 6, 1
• Use lowest effective dose once congestion cleared 5, 6

Implementation Strategy: "Four Drugs in 4 Weeks"

Start all four foundational classes simultaneously at low doses rather than waiting to achieve target doses sequentially 4, 7. This approach:

• Reduces mortality faster than sequential titration
• Allows earlier benefit from each drug class
• Prevents unnecessary delays in life-saving therapy

Titration schedule: Double doses every 2-4 weeks as tolerated, targeting doses proven in clinical trials 5, 4

NYHA Class II Specific Considerations

NYHA Class II patients can be safely initiated and titrated by non-specialist physicians 5. These patients are:

• Stable enough for outpatient initiation
• Less likely to require intensive monitoring than Class III/IV
• Often underdiagnosed and undertreated despite significant benefit potential 8

Critical Monitoring Parameters

After each dose increase, check at 1-2 weeks 5, 9:

• Blood pressure (target systolic >90 mmHg)
• Serum creatinine (up to 30% increase acceptable) 5
• Potassium (keep <5.5 mEq/L)
• Clinical volume status

Avoid triple renin-angiotensin system blockade (ACE inhibitor + ARB + MRA together) due to hyperkalemia risk 1

Medications to AVOID

• Diltiazem or verapamil (Class III recommendation—increase HF worsening and hospitalization) 1
• NSAIDs (worsen renal function and fluid retention) 5, 6, 9
• Most antiarrhythmic drugs (except amiodarone/dofetilide when specifically indicated) 6

Optional/Adjunctive Therapies

Consider adding if symptomatic despite optimal quadruple therapy:

• Hydralazine/isosorbide dinitrate: Particularly for African-American patients (Class IIa) or ACE inhibitor/ARB/ARNI-intolerant patients 5, 4
• Digoxin: For persistent symptoms or atrial fibrillation rate control 9
• Ivabradine: If heart rate >70 bpm on maximally tolerated beta-blocker 4

Common Pitfalls to Avoid

1. Delaying SGLT2 inhibitor initiation while waiting for "optimal" doses of other medications—start early 7, 10
2. Stopping medications for minor creatinine increases (<30% rise is acceptable) 5
3. Using non-evidence-based beta-blockers (only bisoprolol, carvedilol, metoprolol succinate proven) 6, 2
4. Undertreating younger, less symptomatic patients who have most to gain from early aggressive therapy 8, 10
5. Reducing diuretics excessively when starting neurohormonal antagonists—maintain euvolemia 5

Target Dosing Goals

Aim for target doses proven in clinical trials 5, 4, but any dose is better than no therapy. If target doses not tolerated, maintain maximum tolerated doses rather than discontinuing.